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ABSTRACT
Introduction: Patients with type 2 diabetes
(T2DM) are at increased risk for renal
impairment (RI) and, in addition, there is an
age-related decline in renal function. At the
same time, T2DM treatment is more complex
and treatment options are more limited in
elderly patients as well as patients with RI,
with the patient population C75 years with
moderate or severe RI posing unique
challenges, in particular, the high risk and
more severe consequences of hypoglycemia. It
was, therefore, of interest to assess the efficacy
and tolerability of the dipeptidyl peptidase-4
inhibitor vildagliptin in patients with T2DM
C75 years who also have moderate or severe RI.
Methods: In this sub-analysis of data derived
from a previously described randomized, double-
blind, parallel-group, 24-week study, 105 patients
(50 randomized to vildagliptin 50 mg qd and 55
to placebo) C75 years (mean age*78 years) with
T2DM and moderate or severe RI (mean baseline
estimatedglomerular filtration rate*35 ml/min/
1.73 m2) were included.
Results: The adjusted mean change in glycated
hemoglobin (HbA1c) with vildagliptin was
-1.0% from a baseline of 7.8% (between-group
difference -0.8%; p\0.001). This improvement
in glycemic control was not associated with an
increased risk of hypoglycemia; the rate of
confirmed hypoglycemia was 0.49 events per
patient-year with vildagliptin and 0.96 events
per patient-year with placebo (not significant).
Weight remained stable with vildagliptin
treatment. Adverse events (AEs) (58.0% vs.
72.7%), serious AEs (14.0% vs. 16.4%),
discontinuations due to AEs (4.0% vs. 9.1%)
and deaths (0% vs. 5.5%) were reported at a
comparable or lower frequency in patients
receiving vildagliptin versus patients receiving
placebo.
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Conclusion: In this uniquely fragile elderly
population C75 years with T2DM and
moderate or severe RI, vildagliptin was well
tolerated and efficacious, with no increase in
the rate of hypoglycemia compared to placebo
despite the marked improvement in glycemic
control.
Keywords: Dipeptidyl peptidase-4; Elderly;
Renal impairment; Type 2 diabetes; Vildagliptin
INTRODUCTION
The number of elderly individuals suffering
from type 2 diabetes (T2DM) is continuously
growing worldwide. This is related to the overall
aging of the population as well as to a
continuous increase in the prevalence of
T2DM with age, reaching about 20% in adults
aged 75 years or older [1]. These elderly patients
have an increased prevalence of T2DM-related
morbidity and mortality, physical disability and
frailty, cognitive disorders and, in particular,
micro- and macrovascular co-morbidities, such
as congestive heart failure and renal
impairment (RI) [2].
Diabetes is the leading causes of chronic
kidney disease [3], with T2DM patients
accounting for about 1/3 of all cases of end
stage renal disease (ESRD) requiring dialysis [4].
In addition, there is also an age-related decline
in kidney function [5]. Ultimately, between
25% and 40% of patients with T2DM will
develop RI [6]. In a large-scale French survey,
for example, 28% of the population of patients
with T2DM C65 years had moderate RI and this
increased to 37% for patients aged 75–79 years
[7].
The elderly population with T2DM and
moderate or severe RI is a uniquely fragile
population and effective treatment in this
vulnerable population poses special challenges.
These include a high prevalence of
polypharmacy, which increases the risk of
drug–drug interactions, presence of multiple
co-morbidities, and the paucity of clinical data
in this population. Importantly, treatment
options are more limited and/or complex in
this population due to contraindications,
differential clearance and/or metabolism of
anti-hyperglycemic agents, need for dose
adjustment and/or regular monitoring. In
addition, there is a higher risk for side effects,
in particular, a high susceptibility and
dangerousness of hypoglycemia. The risk of
hypoglycemia associated with drug treatment
(insulin secretagogues and insulin) increases
markedly with age [2, 8] and hypoglycemia in
the elderly is associated with more severe
consequences and complications [2]. The risk
of adverse effects is further increased by a
marked unawareness of hypoglycemia in the
elderly population, leading to more frequent
and severe events [9, 10]. Furthermore, RI is also
associated with an increased incidence of
hypoglycemia due to decreased renal
neoglycogenesis [11]. For example, in a
retrospective cohort analysis, the incidence of
hypoglycemia (glucose \70 mg/dL) was 10.72
events per 100 patient-months in diabetic
patients with chronic kidney disease versus
5.33 in those without chronic kidney disease
[12]. Additionally, RI is associated with
differential clearance and/or metabolism of
several anti-hyperglycemic agents; in
particular, consequent overexposure to insulin
secretagogues is often linked to an increased risk
of hypoglycemia [13]. Similarly, the difficulty
with insulin dose selection due to impaired
catabolism and clearance of exogenous insulin
in patients with RI further increases the risk of
hypoglycemia [13].
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Vildagliptin is an inhibitor of dipeptidyl
peptidase 4 (DPP-4) that extends the meal-
induced increases in the levels of the incretin
hormones, glucagon-like peptide 1 (GLP-1)
and glucose-dependent insulinotropic
polypeptide (GIP), thereby improving the
sensitivity and responsiveness of pancreatic
a-cells and b-cells to glucose [14]. This results
in glucose-sensitive modulation of insulin and
glucagon secretion, improving both fasting
and postprandial glycemic control, with a
low risk of hypoglycemia [14]. A
hypoglycemia risk similar to placebo has
consistently been seen with vildagliptin
across a wide spectrum of patients/disease
[15], including elderly patients [2, 16],
patients with RI [17–19] and/or patients
treated with insulin [20]. This included data
from a dedicated 24-week study of vildagliptin
50 mg qd in patients with moderate or severe
RI [17]. In this large study *20% of patients
were 75 years or older, which provided an
opportunity to assess the efficacy and
tolerability of vildagliptin in this particularly
vulnerable and difficult-to-treat elderly T2DM
patient population with RI. Accordingly, the
authors report here the experience with
vildagliptin in patients C75 years with T2DM
and moderate/severe RI based on a sub-
analysis of the afore-mentioned study [17].
MATERIALS AND METHODS
Patients and Study Design
This was a post hoc sub-analysis of data from a
previously described [17] multi-center,
randomized, double-blind, parallel-group,
24-week study that assessed safety and efficacy
of vildagliptin (50 mg qd) versus placebo in 515
patients with T2DM and moderate (n = 294) or
severe (n = 221) RI. The key entry criteria for
this trial included age of 18–85 years, body mass
index (BMI) of 18–42 kg/m2, glycated
hemoglobin (HbA1c) of 6.5–10% and T2DM
either untreated or treated with a sulfonylurea
(SU), alpha-glucosidase inhibitor (AGI),
thiazolidinedione (TZD), insulin, meglitinide
or a combination of agents provided that
doses were stable for at least 4 weeks before
the first study visit. Patients also had to
continue their current diet/exercise regimen
and background therapy unchanged
throughout the duration of the study. The diet
or caloric intake was not specifically monitored
during the study. Addition or intensification of
insulin therapy was defined as initiating rescue
medication. After a 2-week single-blind, placebo
run-in period, eligible patients were randomized
(baseline, BL) to vildagliptin (50 mg qd,
n = 289) or placebo (n = 226). The detailed
design of this study was described previously
[17].
The data analysis presented here includes
only patients with age C75 years, resulting in
105 patients with moderate or severe RI
[estimated glomerular filtration rate (eGFR)
C30 to \50 ml/min/1.73 m2 and \30 ml/min/
1.73 m2, respectively] contributing to the sub-
analysis.
Study Assessments
HbA1c, fasting plasma glucose (FPG), and weight
were regularly assessed at 4-week intervals. The
laboratory assessments were performed by a
central laboratory [Covance (Geneva,
Switzerland, Singapore, or Indianapolis, IN,
USA)]. Responder analysis was also performed
as described below.
Hypoglycemia was defined as symptoms
suggestive of low blood glucose confirmed by
self-monitored blood glucose (SMBG)
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measurement \3.1 mmol/l plasma glucose
equivalent. Severe hypoglycemia was defined
as any episode requiring assistance of another
party (whether or not a confirmatory SMBG
measurement was available).
All adverse events (AEs) were recorded and
assessed by the investigator for severity and
possible relationship to study medication. GFR
was estimated by the Modification of Diet in
Renal Disease study method (MDRD).
Statistical Analysis
The total number of patients and demographic
and clinical characteristics are presented.
The adjusted mean changes (AMD) in HbA1c,
FPG and weight from BL to endpoint [with final
observation carried forward (LOCF)] were
compared between treatments using an
analysis of covariance (ANCOVA) model with
baseline value, background therapy, pooled
center, and treatment as covariates. Data were
censored at initiation of rescue medication.
Responder rates (percentage of patients with
baseline HbA1c C7.5% achieving endpoint
HbA1c \7.5%) were assessed by treatment and
compared by Fisher’s exact test. For
hypoglycemia, event rates per patient-year
(defined as number of events/total subject year
exposure) were compared between treatments
with inference based on a normal
approximation of the Poisson distribution. In
addition, the number of patients experiencing
events and the number of events were
summarized descriptively. Safety data were
summarized descriptively by treatment.
Ethics and Good Clinical Practice
The study underlying this sub-analysis was
conducted in accordance with the Helsinki
Declaration of 1975, as revised in 2000 and 2008
and International Conference on Harmonization/
Good Clinical Practice guidelines. The study
protocol was approved by an independent ethics
committee/institutional review board (IRB) at




One hundred and five patients [50 in the
vildagliptin (50 mg qd) group and 55 in the
placebo group] with moderate or severe RI and
aged 75 years or older at study entry were
included in this analysis. Table 1 summarizes
the demographic and clinical characteristics in
the randomized population. These elderly
patients with moderate or severe RI had a
mean age of 78.1 years and a mean eGFR of
35.3 ml/min/1.73 m2. Nearly 1/3 of patients
C75 years had severe RI and the remaining
about 2/3 of patients had moderate RI. The
randomized patients had a mean HbA1c of 7.8%,
mean FPG of 8.5 mmol/L and mean BMI of
30.5 kg/m2, and were treated mainly with either
insulin (*55%) or oral anti-diabetic drug (OAD)
monotherapy (*25%), or a combination of
insulin and OAD (*13%). As expected,
patients had long-standing T2DM (mean
duration of 16.2 years, with 2/3 of patients
being diagnosed with T2DM for C10 years),
nearly all patients (96.2%) had hypertension
and [2/3 of patients (68.6%) had dyslipidemia.
Furthermore, in line with their advanced age
and T2DM, more than half of the patients
(53.3%) had a high cardiovascular (CV) risk
status, defined as previous history of CV and
cerebrovascular (CCV) events in the Standard
MedDRA Queries (SMQs) of ‘ischemic heart
disease, cardiac failure, ischemic
cerebrovascular conditions and/or embolic/
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thrombotic events arterial’. These disease
characteristics are also reflected in the number
and nature of concomitant medications, with
84.8% of patients taking C5 other medications
(in addition to their anti-diabetic treatment),
95.2% receiving anti-hypertensive medications
and 64.8% being treated with lipid-lowering
agents. The demographic and clinical
characteristics were overall comparable
between the vildagliptin and placebo groups.
EFFICACY
In the patients C75 years with T2DM and
moderate/severe RI receiving vildagliptin
Table 1 Patient demographic and clinical characteristics
(randomized population)




Mean age (years) 78.0 ± 2.5 78.3 ± 2.7
Sex
Male 26 (52.0) 30 (54.5)
Female 24 (48.0) 25 (45.5)
Race
White 44 (88.0) 43 (78.2)
Asian 3 (6.0) 5 (9.1)
Hispanic/latino 3 (6.0) 6 (10.9)
All other 0 (0.0) 1 (1.8)
Mean HbA1c (%) 7.8 ± 1.0 7.9 ± 0.8
Mean FPG (mmol/L) 8.8 ± 3.2 8.2 ± 3.1
Mean weight (kg) 81.2 ± 13.8 79.9 ± 13.9
Mean BMI (kg/m2) 31.0 ± 4.5 30.0 ± 4.4
Mean duration of T2DM
(years)
14.0 ± 9.7 18.1 ± 10.0
Disease duration group (years)
C5 43 (86.0) 47 (85.5)
C10 29 (58.0) 41 (74.5)
Mean eGFR (MDRD)
(ml/min/1.73 m2)
35.5 ± 9.4 35.1 ± 9.5
eGFR group
Moderate (C30 to\50) 36 (72.0) 35 (63.6)
Severe (\30) 14 (28.0) 20 (36.4)
Previous antidiabetic medication [n (%)]
Drug-naive 4 (8.0) 1 (1.8)
Insulin monotherapy 26 (52.0) 32 (58.2)
Insulin and OAD 3 (6.0) 11 (20.0)
OAD monotherapy 17 (34.0) 9 (16.4)
OAD combination
therapy
0 (0.0) 2 (3.6)
Table 1 continued




Hypertension 48 (96.0) 53 (96.4)
Dyslipidemia 36 (72.0) 36 (65.5)
High CV risk statusa 26 (52.0) 30 (54.5)
Concomitant medications at BL (in addition to any anti-
diabetic medications)
C5 Medications 42 (84.0) 47 (85.5)
Anti-hypertensive
medications
47 (94.0) 53 (96.4)
Lipid-lowering
medications
34 (68.0) 34 (61.8)
BL baseline, BMI body mass index, CV cardiovascular,
FPG fasting plasma glucose, GFR glomerular ﬁltration rate,
HbA1c glycated hemoglobin, MDRD modiﬁcation of diet
in renal disease, OAD oral anti-diabetic drug, s.d. standard
deviation, SMQ standardized MedDRA query, SU
sulfonylurea, T2DM type 2 diabetes
a High CV risk status includes patients with a previous
history of CV and cerebrovascular events in the SMQs of
‘‘ischemic heart disease, cardiac failure, ischemic
cerebrovascular conditions and/or embolic thrombotic
events, arterial’’
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50 mg qd added to background therapy, the
AMD in HbA1c from baseline (7.8% ± 0.2%) to
week 24 endpoint was -1.0% ± 0.2%, while in
the patients receiving placebo added to
background therapy the AMD from baseline
(7.9% ± 0.1%) to endpoint was -0.2% ± 0.2%
(Fig. 1a). This resulted in a significant between-
group difference (vildagliptin–placebo) of
-0.8% ± 0.2% (p\0.001). The percentage of
vildagliptin-treated patients (with baseline
HbA1c [7.5%) achieving endpoint HbA1c
B7.5%, a target consistent with the vulnerable
patient population [3, 21, 22], was nearly twice
that reported in the placebo group (51.9% vs.
26.3%).
FPG also decreased with vildagliptin. The
AMD in FPG in the vildagliptin group was
-1.1 ± 0.6 mmol/L (baseline 8.9 ± 0.5 mmol/
L); however, the between-treatment difference
(-0.9 ± 0.5 mmol/L) did not achieve statistical
significance (p = 0.088).
Body weight remained stable in the
vildagliptin group; baseline weight averaged
81.1 ± 2.0 kg and the AMD was 0.4 ± 0.7 kg. In
the placebo group, the AMD was -1.0 ± 0.7 kg
from a baseline of 79.8 ± 1.9 kg (p = 0.015 vs.
vildagliptin).
The markedly lower glucose level achieved
with vildagliptin vs. placebo added to
background therapy was not associated with
an increased risk of hypoglycemia. Figure 1b
shows the frequency of confirmed
hypoglycemia over 24 weeks of treatment. The
rate of hypoglycemia was 0.49 events per
patient-year with vildagliptin and 0.96 events
per patient-year with placebo (not significant;
p = 0.970). Expressed in absolute number of
events, in the vildagliptin group 5 patients
Fig. 1 a Adjusted mean (±SEM) change from baseline to
week 24 endpoint in HbA1c in patients adding vildagliptin
50 mg qd (n = 49) or placebo (n = 55) to their ongoing
background therapy; *p\0.001 (between-group difference).
An ANCOVA model with baseline value, background
therapy, pooled center and treatment as covariates was used.
b Events per patient-year of hypoglycemia during 24-week
treatment with vildagliptin 50 mg qd (n = 50) or placebo
(n = 55) added to their ongoing background therapy;
p = 0.970 (between-group difference). BL baseline
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reported a total of 11 events, while in the
placebo group 4 patients reported a total of 23
events. Furthermore, severe hypoglycemia (i.e.
requiring assistance of another party) was rare
in both treatment groups (experienced by 1
patient in the vildagliptin group and 0 patients
in the placebo group), and no patients in either
treatment group discontinued due to
hypoglycemia.
Safety and Tolerability
The overall AE profile was similar in elderly
patients with moderate/severe RI receiving
vildagliptin or placebo (Table 2).
Adverse events (58.0% vs. 72.7%) and
discontinuations due to AEs (4.0% vs. 9.1%)
were reported with a somewhat lower frequency
in elderly patients with moderate/severe RI
receiving vildagliptin than in patients
receiving placebo, and the incidence of serious
AEs (SAEs) was similar in the two treatment
groups (14.0% vs. 16.4%) (Table 2). No patient
in the vildagliptin treatment group died, while
3 patients (5.5%) died in the placebo group (1
myocardial infarction, 1 cardiogenic shock, and
1 upper gastrointestinal hemorrhage) (Table 2).
When system organ classes (SOCs) of interest
in this elderly patient population with
moderate/severe RI were analyzed (Table 2),
lower incidences of AEs were reported with
vildagliptin vs. placebo in the SOCs of cardiac
disorders (4.0% vs. 18.2%; the difference not
being driven by a particular type of event) and
gastrointestinal disorders (8.0% vs. 20.0%; with
the largest difference seen for diarrhea). The AE
rates in the SOCs of infections and infestations,
musculoskeletal and connective tissue
disorders, nervous system disorders and skin
and subcutaneous tissue disorders were overall
similar between vildagliptin and placebo. As
further detailed in Table 2, the most commonly
reported specific AEs were edema (12.0% with
vildagliptin vs. 16.4% with placebo),
nasopharyngitis (12.0% vs. 7.3%) and dizziness
(4.0% vs. 14.5%). Most of the AEs in both
treatment groups were mild or moderate, with
only 8.0% of patients in the vildagliptin group
and 12.7% of patients in the placebo group
experiencing severe events.
Table 2 Adverse events (safety set)
Vildagliptin




AEs 29 (58.0) 40 (72.7)
SAEs 7 (14.0) 9 (16.4)
Discontinuation due to
AEs
2 (4.0) 5 (9.1)
Deaths 0 (0.0) 3 (5.5)
AEs in SOCs
Cardiac disorders 2 (4.0) 10 (18.2)
Gastrointestinal disorders 4 (8.0) 11 (20.0)
Infections and
infestations




8 (16.0) 9 (16.4)
Nervous system disorders 9 (18.0) 15 (27.3)
Skin and subcutaneous
tissue disorders
5 (10.0) 8 (14.5)
Most common AEs by preferred terma
Edema 6 (12.0) 9 (16.4)
Nasopharyngitis 6 (12.0) 4 (7.3)
Dizziness 2 (4.0) 8 (14.5)
Fatigue 3 (6.0) 3 (5.5)
Hyperhidrosis 1 (2.0) 5 (9.1)
AE adverse event, n number of patients with an AE, SAE
serious adverse event, SOC system organ class
a C10% in the study
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There was no deterioration of renal function
with vildagliptin after 24 weeks of treatment as
assessed by the eGFR (change from baseline
-0.1 vs. -2.0 ml/min/1.73 m2 with placebo).
DISCUSSION
The present sub-analysis evaluated vildagliptin
in the uniquely vulnerable elderly population
C75 years with T2DM and moderate or severe
RI, many of whom (nearly 70%) were treated
with insulin. The main finding was that
vildagliptin was efficacious, with no increase
in the rate of hypoglycemia compared to
placebo despite a marked improvement in
glycemic control.
The magnitude of the glucose-lowering seen
in this subgroup (HbA1c reduction of -1.0%
from a baseline of 7.8%) was similar to that seen
previously in patients C75 years with mostly
normal renal function or mild RI receiving
vildagliptin monotherapy or add-on therapy to
metformin (-0.9% to -1.1%) [16] or in a
population with severe RI with a mean age of
64 years receiving background insulin therapy
(-0.9%) [18], which was also reported to be
consistent with that seen for vildagliptin in the
general population in monotherapy or
combination therapy studies. Relative to
placebo, the decrease in HbA1c (-0.8%) was
clinically meaningful, with more than half of
the vildagliptin-treated patients reaching an
HbA1c B7.5%, regarded an appropriate target
for this patient population [3, 21, 22]. Thus, the
metabolic derangements clearly manifested in
this patient population with advanced age, RI,
and long-standing mainly insulin-treated T2DM
[23] did not adversely affect the efficacy of
vildagliptin. The small HbA1c reduction
(-0.2%) seen in the control group is likely a
study effect and not unusual for patients
entering a placebo-controlled trial.
Hypoglycemia is a major limiting barrier to
good glycemic control even in the general
population [15]. In light of the markedly
increased risk of hypoglycemia, including severe
hypoglycemia, in a highly vulnerable patient
population of advanced age, with RI and
significant insulin use [2, 8–12] and given the
more severe consequences of hypoglycemia in
these patients (including events like falls and
fractures [2]), as well as the potential CV risk
associated with severe hypoglycemia [2, 24], the
finding that there was no increase in the rate of
hypoglycemia with vildagliptin despite the
meaningful decrease in mean HbA1c (7.8% to
6.8%) is noteworthy. The rate of confirmed
hypoglycemia was 0.49 vs. 0.96 events per
patient-year with vildagliptin and placebo,
respectively, with a very low incidence of severe
hypoglycemia (1 patient on multiple insulin
injections in the vildagliptin group, precipitated
by alcohol consumption, and 0 patients in the
placebo group) and no discontinuations due to
hypoglycemia. While an improvement in
glycemic control in the range reported in the
current analysis would generally be expected to
be associated with an increase in hypoglycemia,
in particular, in the patient population studied,
the protection against hypoglycemia seen with
vildagliptin has a mechanistic basis, likely being
mediated via a GIP-induced increase in glucagon
levels whenever glucose levels fall into the
hypoglycemic range [14, 20]. Vildagliptin
treatment extends the physiological meal-
related increases of the incretin hormones into
the inter-meal and overnight periods and
vildagliptin was shown to enhance the glucagon
counter-regulatory response to hypoglycemia
during a stepped clamp versus placebo in drug-
naı¨ve patients with T2DM [14, 25].
Consistent with the weight neutrality
generally reported for vildagliptin [26]
including in insulin-treated patients [20], there
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was only a minimal weight change (0.4 kg)
reported for vildagliptin when added to
background therapy in the elderly patient
group with moderate/severe RI.
The safety and tolerability of vildagliptin in a
wide range of disease stages including pooled
analyses from a large clinical database was
assessed in detail previously [16, 17, 20, 27–
29]. The results from the present investigation
are consistent with the safety and tolerability
profile reported earlier, with no new safety
signals identified in the present sub-analysis.
While a numerically lower percentage of
vildagliptin-treated patients experienced
events in the SOC of Cardiac disorders (4% vs.
18.2%), a trend similar to that seen in an earlier
pooled analysis of elderly patients C75 years
[16], this was not driven by any particular type
of events and based on a very small number of
events, thus limiting definitive conclusions.
In light of the broader applicability of the
reported results, while inclusion/exclusion
criteria in clinical trials can restrict the
demographic and disease characteristics
compared to a real life setting, the patients
studied in the present analysis were overall
reflective of an elderly patient population with
advanced renal insufficiency, thus further
extending the findings of a previously pooled
analysis of a patient population C75 years with
mainly normal renal function or mild RI [16]
and of a study in a population C70 years
including a small percentage of patients with
moderate RI (14.4%) but no patients with severe
RI [30]. The latter study showed that nearly
twice as many patients reached individualized
treatment targets with vildagliptin than placebo
added to their background therapy, with
comparable safety and tolerability. In the
present sub-analysis, nearly 1/3 of patients
C75 years had severe RI and the remaining
about 2/3 of patients had moderate RI, with a
mean eGFR of 35 ml/min/1.73 m2. In addition
to the renal comorbidity, patients also had a
high prevalence of CV risk factors [including
obesity (mean BMI 30.5 kg/m2), long-standing
T2DM (mean duration of 16.2 years, with 2/3 of
patients being diagnosed for C10 years),
hypertension ([90%), dyslipidemia ([2/3)],
and [50% had a high CV risk status based on
previous CCV history. These factors, together
with the fact that *70% of patients were
treated with insulin and *85% of patients
taking C5 other medications (in addition to
their anti-diabetic treatment), highlight the
uniquely fragile/vulnerable characteristics of
the studied population. It is worth noting,
however, that while the mean age of the
population was 78.1 years, the upper age of
the patients was 85 years, thus the data cannot
necessarily be extrapolated to a population of
[85 years. Another limitation of the present
investigation is that the results are based on a
sizeable yet limited number of patients.
Furthermore, information that would have
allowed to characterize the population with
respect to dependency (e.g. care home
residency) or mental status is lacking.
CONCLUSION
Taken together, the present sub-study provides
valuable information regarding the experience
with vildagliptin in the difficult-to-treat elderly
population C75 years with T2DM and moderate
or severe RI.
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